Cargando…

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial

BACKGROUND: Concurrent chemoradiotherapy is currently the standard of care for patients with locally advanced cervical cancer. However, even with the application of modern radiotherapy techniques, a considerable number of patients still develop distant metastases. PD-L1 inhibitors show good efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jie, Li, Chen, Cao, Yuanjie, Zhu, Li, Zhang, Bailin, You, Jinqiang, Hou, Hailing, Wang, Jing, Yuan, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295395/ https://www.ncbi.nlm.nih.gov/pubmed/35854236 http://dx.doi.org/10.1186/s12885-022-09866-w

Ejemplares similares

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
por: Hua, Yijun, et al.
Publicado: (2021)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
por: Jiang, Wei, et al.
Publicado: (2022)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial
por: Chen, Si-Yuan, et al.
Publicado: (2023)

Correction to: Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
por: Jiang, Wei, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
por: Lan, Mei, et al.
Publicado: (2017)

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Analysis of Treatment Outcomes and Prognosis After Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
por: Peng, Qing-he, et al.
Publicado: (2022)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial
por: Huang, Xiaotao, et al.
Publicado: (2022)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
por: Kadkhodayan, Sima, et al.
Publicado: (2013)

Quality of Life in Cervical Cancer Survivors Treated with Concurrent Chemoradiotherapy
por: Stuopelytė, Raminta, et al.
Publicado: (2023)

A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy
por: Wu, Ning, et al.
Publicado: (2021)

Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women
por: Wang, Weiping, et al.
Publicado: (2017)

Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT)
por: Wu, Lei, et al.
Publicado: (2022)

Platinum Plus Tegafur–Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis
por: Lien, Ching-Feng, et al.
Publicado: (2022)

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
por: Chen, Qiuyan, et al.
Publicado: (2018)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
por: Liu, Haonan, et al.
Publicado: (2022)

Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma
por: Yang, Jie, et al.
Publicado: (2016)

Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
por: Hattori, Satomi, et al.
Publicado: (2021)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
por: Chen, Yongbiao, et al.
Publicado: (2023)

The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer
por: Zhang, Bao-Zhong, et al.
Publicado: (2023)

Potentialities of multi-b-values diffusion-weighted imaging for predicting efficacy of concurrent chemoradiotherapy in cervical cancer patients
por: Liu, Bing, et al.
Publicado: (2020)

Intravoxel incoherent motion diffusion-weighted imaging evaluated the response to concurrent chemoradiotherapy in patients with cervical cancer
por: Bian, Hao, et al.
Publicado: (2019)

Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer
por: Wei, Li-Chun, et al.
Publicado: (2018)

Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy
por: Li, Yong, et al.
Publicado: (2021)

High expression of FUNDC1 predicts poor prognostic outcomes and is a promising target to improve chemoradiotherapy effects in patients with cervical cancer
por: Hou, Hailing, et al.
Publicado: (2017)

Adjuvant hysterectomy in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
por: Shim, Seung-Hyuk
Publicado: (2019)

Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports
por: Wakayama, Akihiko, et al.
Publicado: (2017)

Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
por: Zhang, Guoqing, et al.
Publicado: (2023)

Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients
por: Guo, Zhen, et al.
Publicado: (2017)

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021)

Regarding the study testing the addition of gemcitabine to concurrent chemoradiotherapy in cervical carcinoma: Clarity needed
por: Revannasiddaiah, Swaroop, et al.
Publicado: (2013)

Spontaneous ureteral rupture during concurrent chemoradiotherapy in a woman with uterine cervical cancer
por: Ikeda, Shun-ichi, et al.
Publicado: (2015)

Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
por: Liu, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lbr4m8c0282bmtep2mi2r32euj